Patient demographics and baseline characteristics
| . | N = 17 . |
|---|---|
| Characteristics | |
| Mean age (range), y | 39 (23-55) |
| Sex, no. (%) | |
| Female | 6 (35.3) |
| Male | 11 (64.7) |
| African or African American race, no. (%) | 17 (100) |
| Hb SS genotype, no. (%) | 17 (100) |
| Hydroxyurea use, no. (%) | 12 (70.6) |
| l-glutamine use, no. (%) | 1 (5.9) |
| Eligible for 50-mg dose level, no. | 16 |
| Eligible for 100-mg dose level, no. | 9 |
| Baseline laboratory measures | N = 16 |
| Mean hemoglobin (SD), g/dL | 9.2 (1.1) |
| Mean absolute reticulocyte count (SD), K/μL | 188.2 (99.2) |
| Mean total bilirubin (SD), mg/dL | 2.0 (0.9) |
| Mean lactate dehydrogenase (SD), U/L | 375.2 (120.6) |
| Median hemoglobin F, % (25th, 75th percentile) | 21.6 (12.4, 26.9) |
| Median ferritin (25th, 75th percentile), mcg/L | 177 (110, 318.25) |
| . | N = 17 . |
|---|---|
| Characteristics | |
| Mean age (range), y | 39 (23-55) |
| Sex, no. (%) | |
| Female | 6 (35.3) |
| Male | 11 (64.7) |
| African or African American race, no. (%) | 17 (100) |
| Hb SS genotype, no. (%) | 17 (100) |
| Hydroxyurea use, no. (%) | 12 (70.6) |
| l-glutamine use, no. (%) | 1 (5.9) |
| Eligible for 50-mg dose level, no. | 16 |
| Eligible for 100-mg dose level, no. | 9 |
| Baseline laboratory measures | N = 16 |
| Mean hemoglobin (SD), g/dL | 9.2 (1.1) |
| Mean absolute reticulocyte count (SD), K/μL | 188.2 (99.2) |
| Mean total bilirubin (SD), mg/dL | 2.0 (0.9) |
| Mean lactate dehydrogenase (SD), U/L | 375.2 (120.6) |
| Median hemoglobin F, % (25th, 75th percentile) | 21.6 (12.4, 26.9) |
| Median ferritin (25th, 75th percentile), mcg/L | 177 (110, 318.25) |